Instituto Nacional de Cancer, Brazil: Phase 1 study completed, 20 enrolled (Head and Neck Neoplasms, Mucositis Oral)
Instituto Nacional de Cancer, Brazil: Phase 1 study completed, 20 enrolled (Head and Neck Neoplasms, Mucositis Oral). Its enrollment of 20 is below the median of 80 (11th percentile). Dated 23 days ago, it is in the active follow-up window. Score 30/100. As of 2026-11-04, from ClinicalTrials.gov (U.S. National Library of Medicine) API v2.
Data as of · Compiled by Zalwin from ClinicalTrials.gov (U.S. National Library of Medicine) API v2
enrollment: 20 · 11th percentile of 8,879 ClinicalTrialStartPulse records · 0.3x the median
Free preview: all 15 published fields of this record are shown below. Locked: 499 related ClinicalTrialStartPulse records and the 7-column CSV export.
| Field | Value |
|---|---|
| Sponsor | Instituto Nacional de Cancer, Brazil |
| Sponsor type | Non-US government |
| Study | Safety and Tolerability of the Use of Copaiba in Patients With Oral Cancer Submitted to Radiotherapy |
| NCT ID | NCT05308732 |
| Phase | Phase 1 |
| Status | completed |
| Conditions | Head and Neck Neoplasms; Mucositis Oral; Radiotherapy; Complications |
| Intervention types | drug |
| Target enrollment | 20 |
| Site countries | Brazil |
| Posted | 2022-04-04 |
| Planned start | 2021-05-11 |
| Event | Completed |
| Event date | 2026-09-30 |
| Last update posted | 2026-10-13 |
| enrollment percentile | 11th of 8,879 (median 80, 0.3x median) |
| Peer records CSV (500 records) | 🔒 Click to unlock → |
| CRM-ready export with official source URLs | 🔒 Click to unlock → |
Watch Instituto Nacional de Cancer, Brazil
Free email alert. Alert me when this company gets a new filing, lien, permit, contract or expiry in this feed. One confirmation email; unsubscribe any time.
Free for 1 company. More companies from $9/mo (25), $49/mo (500 + CSV), $199/mo (500 + CSV + API). Cancel any time from the link in every email.
Unlock Instituto Nacional de Cancer, Brazil + 500 peer records (CSV)
Instant CSV download · Card, Apple Pay, Google Pay or Link via Stripe · No account required
CSV columns: Sponsor · Phase · Conditions · Enrollment · Countries · Event · Posted · official source URL
- Source agency: ClinicalTrials.gov (U.S. National Library of Medicine) API v2
- Record date: 2026-10-13
- Data refreshed: 2026-11-04
- Refunds on request within 14 days
Top ClinicalTrialStartPulse records (NONUS first): University of Oxford · DejthidaNathaphong · Eye & ENT Hospital of Fudan University · Shanghai First Maternal and Infant Health Hospital affiliate · Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Browse all by state and category →
LIVE PUBLIC DATA Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 · Last refreshed: Wed, 04 Nov 2026 06:04:38 GMT
Is this your business? Add a "Listed on Zalwin" badge to your site
Paste this snippet into your website. It links to this public record; nothing is tracked on your site.
Peer benchmark and outreach value: Instituto Nacional de Cancer, Brazil and 6,603 NONUS peers
- NONUS ClinicalTrialStartPulse records like this one: 6,603
- Instituto Nacional de Cancer, Brazil's enrollment: 11th percentile of 8,879 records
- Timing: Medium: dated in the last 30 days
- Estimated pipeline if you contact every NONUS peer: $1,320,600 (peers × rate × deal size; an estimate from your assumptions, not a forecast)
30 / 100 Score
- Completed: closeout, analysis and the next study ahead.
What is the ClinicalTrialStartPulse record for Instituto Nacional de Cancer, Brazil?
Instituto Nacional de Cancer, Brazil's Phase 1 study (NCT05308732) in Head and Neck Neoplasms, first posted 2022-04-04: completed (2026-09-30), in an update posted 2026-10-13.
How does Instituto Nacional de Cancer, Brazil compare to other ClinicalTrialStartPulse records?
Its enrollment of 20 is below the median (11th percentile); smaller records often move faster and face less competition. It is 23 days old, still within a typical 45-day follow-up window. Its Score of 30/100 is modest; treat it as background rather than a priority.
Instituto Nacional de Cancer, Brazil vs. top 2 peers
| Organization | Location | Amount | Percentile | Record date |
|---|---|---|---|---|
| Instituto Nacional de Cancer, Brazil | NONUS | 20 | 11th | 2026-10-13 |
| Jiangsu Simcere Pharmaceutical Co., Ltd. | NONUS | 270 | 81st | 2026-11-03 |
| Mabsoft Therapeutics (Shanghai) Co., Ltd. | NONUS | 420 | 88th | 2026-10-28 |
Related records
- Hoffmann-La Roche
- MacroGenics
- Mabsoft Therapeutics (Shanghai) Co., Ltd.
- Sutro Biopharma, Inc.
- Janssen Research & Development, LLC
- Janssen Research & Development, LLC
- Janssen Research & Development, LLC
- Janssen Research & Development, LLC
- Jiangsu Simcere Pharmaceutical Co., Ltd.
- Janssen Research & Development, LLC
- Janssen Research & Development, LLC
- Genentech, Inc.
ClinicalTrialStartPulse: Phase 1 ClinicalTrialStartPulse: Outside the US only
How to monitor Instituto Nacional de Cancer, Brazil and peer phase 1 records
Get new ClinicalTrialStartPulse records like Instituto Nacional de Cancer, Brazil by email (free, weekly)
We email one confirmation link now; the weekly digest starts only after you confirm. One-click unsubscribe in every email.
Double opt-in: nothing is sent until you click the confirmation link. One-click unsubscribe.
Get new studies in your therapeutic areas
ClinicalTrialStartPulse emails new studies and status changes matching your events, phases, sponsor types and site regions.
✓ Read-only, live public data · Key and unlock right after payment · Card, Apple Pay, Google Pay or Link via Stripe · Refunds on request within 14 days
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.